ACTU (Actuate Therapeutics, Inc. Common stock) Stock Analysis - Analyst Ratings

Actuate Therapeutics, Inc. Common stock (ACTU) is a publicly traded Healthcare sector company. As of May 21, 2026, ACTU trades at $2.51 with a market cap of $58.14M and a P/E ratio of -2.36. ACTU moved +3.33% today. Year to date, ACTU is -60.41%; over the trailing twelve months it is -76.32%. Its 52-week range spans $1.58 to $11.99. Analyst consensus is buy with an average price target of $13.50. Rallies surfaces ACTU's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What do analysts rate ACTU?

2 analysts cover ACTU: 0 strong buy, 2 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $13.50.

ACTU Key Metrics

Key financial metrics for ACTU
MetricValue
Price$2.51
Market Cap$58.14M
P/E Ratio-2.36
EPS$-1.06
Dividend Yield0.00%
52-Week High$11.99
52-Week Low$1.58
Volume10
Avg Volume0
Revenue (TTM)$0
Net Income$-22.23M
Gross Margin0.00%

ACTU Analyst Consensus

2 analysts cover ACTU: 0 strong buy, 2 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $13.50.

Latest ACTU News

Recent ACTU Insider Trades

  • THOMSON TODD S sold 280.00K (~$1.62M) on Jan 5, 2026.
  • Bios Equity COF, LP bought 71.43K (~$500.00K) on Jun 27, 2025.
  • Kreis Leslie W. bought 71.43K (~$500.00K) on Jun 27, 2025.

Common questions about ACTU

What do analysts rate ACTU?
2 analysts cover ACTU: 0 strong buy, 2 buy, 0 hold, 0 sell, and 0 strong sell. The consensus rating is buy. The average price target is $13.50.
Does Rallies show ACTU price targets?
Yes. Rallies tracks ACTU analyst ratings, consensus rating, average price target, upgrades, downgrades, analyst firms, and recent price target changes when available.
Is ACTU research on Rallies investment advice?
No. Rallies provides research, data, and educational context for ACTU. It does not provide personalized investment advice.
ACTU

ACTU